In this issue:
- Impact of prior ICIs on dacarbazine efficacy in metastatic melanoma
- User perceptions of mobile health apps for skin cancer screening
- Adding targeted therapy to anti-PD1 after BRAF-metastatic melanoma progresses on ICIs
- Type 2 diabetes increases melanoma aggressiveness
- Pembrolizumab crossover/rechallenge on melanoma recurrence in EORTC 1325-MG/KEYNOTE-054
- Clinical characteristics and prognosis of acral lentiginous melanoma
- Adjuvant treatment for melanoma in real-world clinical practice
- CTCL and risk of second malignancies
- First-line bempegaldesleukin + nivolumab for metastatic melanoma
- Watchful waiting for BCCs
Please login below to download this issue (PDF)